AnnickDesjardinsMDFRCPC

Neurology • Durham, NC

Neurooncology

Associate Professor of Neurology, Duke University School of Medicine

Join to view full profile

Dr. Desjardins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Desjardins' full profile

Already have an account?

Office
20 Duke Medicine Cir
Durham, NC 27710
Phone+1 919-684-8111

Fax+1 919-684-6674

Education & Training

University Sherbrooke Faculty Medicine HospitalNeurology, 1998 - 2003
University of Sherbrooke Faculty of MedicineClass of 1998

Certifications & Licensure

NC State Medical License 2003 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) Start of enrollment: 2007 Apr 01
Completed
Phase 2
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Start of enrollment: 2007 Jul 01
Completed
Phase 2
Ph I Dasatinib + Erlotinib in Recurrent MG Start of enrollment: 2008 Jan 01
Completed
Phase 1
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas Start of enrollment: 2005 Oct 01
Completed
Phase 1
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG Start of enrollment: 2005 May 01
Completed
Phase 1
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas Start of enrollment: 2008 Feb 01
Completed
Phase 1
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Start of enrollment: 2006 Feb 01
Completed
Phase 2
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma Start of enrollment: 2009 Jun 01
Withdrawn
Phase 1
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) Start of enrollment: 2008 Dec 01
Terminated
Phase 2
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) Start of enrollment: 2009 Sep 01
Completed
Phase 2
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma Start of enrollment: 2009 Nov 01
Completed
Phase 1
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma Start of enrollment: 2009 Dec 30
Completed
Phase 2
Study of Immunotoxin, MR1-1 Start of enrollment: 2006 Nov 01
Terminated
Phase 1
Panitumumab and Irinotecan for Malignant Gliomas Start of enrollment: 2010 Feb 01
Terminated
Phase 2
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2011 Apr 01
Terminated
Phase 2
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma Start of enrollment: 2012 Jun 01
Completed
Phase 1
Bevacizumab Beyond Progression (BBP) Start of enrollment: 2013 Jan 01
Completed
Phase 2
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Start of enrollment: 2014 May 01
Terminated
Phase 1
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma Start of enrollment: 2016 Feb 01
Completed
Phase 2
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM Start of enrollment: 2018 May 30
Terminated
Phase 1
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis Start of enrollment: 2019 Jan 31
Terminated
Phase 2
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab Start of enrollment: 2020 Aug 26
Active, not recruiting
Phase 2
Monocyte Antigen Carrier Cells for Newly Diagnosed GBM Start of enrollment: 2023 Aug 01
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

478 citations
Recurrent glioblastoma treated with recombinant poliovirus
Annick Desjardins, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi
The New England Journal of Medicine. 2018-06-26
18 citations
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
Kirit Singh, Kelly M Hotchkiss, Ian F Parney, John De Groot, Solmaz Sahebjam
Nature Medicine. 2023-10-01
1047 citations
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
James J. Vredenburgh, Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon
Journal of Clinical Oncology. 2007-10-20

Lectures

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

The EndBrainCancer Initiative to Feature Renowned Brain Cancer and Modified Poliovirus Duke Researcher, Dr. Annick Desjardins, as Its Keynote Speaker for the 2019 Annual May "Brains Matter" ACTION Dinner as Advocacy Is Underway Now to Bring This Treatm...May 9th, 2019
Early Results for Oncolytic Viruses as a Treatment for Glioblastoma in Both Adults and ChildrenAugust 24th, 2018
Doctors Are Using Herpes Virus to Fight Brain Cancer, and It’s WorkingAugust 17th, 2018
Join now to see all